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Abstract
Endometrial cancer is the most common gyne-
cological malignancy in well-developed coun-
tries. Biologically and clinicopathologically, 
endometrial carcinomas are divided into two 
types: type 1 or estrogen- dependent carcinomas 
and type 2 or estrogen-independent carcinomas. 
Type 1 cancers correspond mainly to endome-
trioid carcinomas and account for approxi-
mately 90 % of endometrial cancers, whereas 
type 2 cancers correspond to the majority of the 
other histopathological subtypes.
The vast majority of endometrial cancers 
present as abnormal vaginal bleedings in 
postmenopausal women. Therefore, 75 % of 
cancers are diagnosed at an early stage, which 
makes the overall prognosis favorable.
The first diagnostic step to evaluate women 
with an abnormal vaginal bleeding is the mea-
surement of the endometrial thickness with 
transvaginal ultrasound. If endometrial thick-
ening or heterogeneity is confirmed, a biopsy 
should be performed to establish a definite 
histopathological diagnosis.
Magnetic resonance imaging is not considered 
in the International Federation of Gynaecology 
and Obstetrics staging system. Nonetheless it 
plays a relevant role in the preoperative staging of 
endometrial carcinoma, helping to define the best 
therapeutic management. Moreover, it is impor-
tant in the diagnosis of treatment complications, 
in the surveillance of therapy response, and in the 
assessment of recurrent disease.
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1  Endometrial Cancer: 
Background
1.1  Epidemiology
Endometrial cancer is the fifth most common malig-
nancy in females worldwide, after breast, colorec-
tal, cervical, and lung cancers, accounting for 4.8 % 
of all cancers in women (Ferlay et al. 2013).
In contrast to cervical cancer, endometrioid can-
cer peak incidence rates occur in well- developed 
countries (Europe and North America), where it is 
the most common gynecological malignancy 
(Ferlay et al. 2013). This is probably due to life-
style factors, in particular obesity, which has been 
linked to about 50 % endometrial cancers in these 
countries (Epstein and Blomqvist 2014; Calle and 
Kaaks 2004). The increase in life expectancy is 
also responsible for its rising (Koh et al. 2014).
Endometrial cancer is more likely to occur in 
postmenopausal women in their sixth and seventh 
decades, with cases only rarely reported under 
the age of 35 in the United Kingdom (Patel et al. 
2010; Cancer Incidence Statistics 2015).
Despite its relatively high prevalence, approx-
imately 82 % of endometrial cancers are diag-
nosed at an early stage, which makes its overall 
prognosis favorable (Cancer Incidence Statistics 
2015). Its worldwide mortality rate is low and it 
has been estimated at 2.2 % (Ferlay et al. 2013).
1.2  Pathology and Risk Factors
The World Health Organization (WHO) classifi-
cation of uterine corpus tumors was revised in 
2014 (Kurman et al. 2014). Endometrial carcino-
mas (also known as adenocarcinoma of the endo-
metrium) are classified under the “Epithelial 
Tumours and Precursors” group and clinicopath-
ologically divided into the following types: endo-
metrioid carcinoma; mucinous carcinoma; serous 
endometrial intraepithelial carcinoma; serous 
carcinoma; clear-cell carcinoma; neuroendocrine 
tumors; mixed cell adenocarcinoma; undifferen-
tiated carcinoma; and dedifferentiated carcinoma 
(Table 1) (Kurman et al. 2014).
Although carcinosarcoma belongs to the 
“Mixed Epithelial and Mesenchymal Tumours” 
group of the uterine corpus, it should be staged as 
an endometrial carcinoma (Kurman et al. 2014).
Biologically and clinicopathologically, endo-
metrial carcinomas are divided into two types: type 
1 or estrogen-dependent carcinomas and type 2 or 
estrogen-independent carcinomas (Table 2).
Type 1 correspond mainly to endometrioid 
carcinomas and accounts for approximately 90 % 
of endometrial cancers, whereas type 2 cancers 
correspond to the majority of the other histopath-
ological subtypes (Epstein and Blomqvist 2014).
Type 1 endometrial cancers are associated 
with prolonged unopposed estrogen exposure, 
therefore with the following risk factors: estrogen 
replacement therapy; tamoxifen therapy for 
breast cancer; polycystic ovarian syndrome; 
estrogen producing ovarian tumors; obesity (con-
version of androgen to estrone in adipose tissue); 
diabetes; early menarche and late menopause and 
nulliparity (Shapiro et al. 1985; Fisher et al. 
1994; Renehan et al. 2008; Soliman et al. 2006; 
McPherson et al. 1996).
Endometrioid cancers are endometrial glandu-
lar neoplasms that can be preceded or associated 
Table 1 World Health Organization classification of epi-
thelial tumors and precursors of the uterine corpus
Precursors
  Hyperplasia without atypia
  Atypical hyperplasia/endometrioid intraepithelial 
neoplasia
Endometrial cancer
  Endometrioid carcinoma
  Squamous differentiation
  Villoglandular
  Secretory
  Mucinous carcinoma
  Serous endometrial intraepithelial carcinoma
  Serous carcinoma
  Clear-cell carcinoma
  Neuroendocrine tumors
  Low-grade neuroendocrine tumor (carcinoid 
tumor)
  High-grade neuroendocrine carcinoma (small cell 
neuroendocrine carcinoma; large cell 
neuroendocrine carcinoma)
  Mixed cell adenocarcinoma
  Undifferentiated carcinoma
  Dedifferentiated carcinoma
Adapted from Kurman et al. (2014)
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with endometrial hyperplasia (Kurman et al. 2014; 
Colombo et al. 2013). They are subdivided into 
three grades of differentiation (well to poorly dif-
ferentiated) according to the amount of solid com-
ponents (Colombo et al. 2013; Tirumani et al. 
2013). Low-grade tumors are usually diagnosed at 
an early stage and generally have a good outcome, 
whereas high-grade endometrioid cancers are asso-
ciated with a poor prognosis (Tirumani et al. 2013).
Endometrioid cancers are characteristically 
associated with PTEN, K-RAS, and CTNNB 
gene mutations (Tirumani et al. 2013).
Mucinous carcinomas are a rare form of type 1 
endometrial cancer, where more than 50 % of 
glandular cells mucin can be found. They are in 
the majority of times well differentiated and 
associated with good prognosis (Kurman et al. 
2014; Jalloul et al. 2012).
Type 2 tumors are constituted by the other his-
tological types, namely, serous carcinoma and 
clear-cell carcinoma (Tirumani et al. 2013; 
Jalloul et al. 2012). They have a more aggressive 
clinical behavior, a poorer prognosis, and are 
usually diagnosed at higher stage (Tirumani et al. 
2013; Jalloul et al. 2012).
Genetics changes such as p53 and p16 inactiva-
tion genes and gene overexpression of HER-2/neu 
are frequently present in these types of carcinomas 
(Tirumani et al. 2013; Hecht and Mutter 2006).
Although classically considered estrogen- 
independent cancers, Setiawan and her col-
leagues found an overlap between risk factors of 
type 1 and type 2 endometrial cancers (Setiawan 
et al. 2013). Parity, oral contraceptives use, age at 
menarche, diabetes and smoking were associated 
with both type 2 (mainly serosal and mixed carci-
nomas) and type 1 cancers (Setiawan et al. 2013). 
The risk factors of type 2 endometrial cancer and 
high-grade endometrioid tumors were similar, 
whereas body mass index was more associated 
with type 1 cancer (Setiawan et al. 2013).
Serous carcinomas make up the majority of 
type 2 endometrial cancers. They are character-
ized by the presence of complex papillary archi-
tecture associated with remarkable nuclear 
pleomorphism (Kurman et al. 2014). They are 
not associated with endometrial hyperplasia, but 
may be preceded by serous endometrial intraepi-
thelial carcinoma, a noninvasive form of carci-
noma confined to the epithelium that generally 
develops in a polyp or in an atrophic endome-
trium (Kurman et al. 2014).
Clear-cell carcinoma is a rare form of type 2 
cancer that resembles its ovarian counterpart 
(Kurman et al. 2014).
Undifferentiated and dedifferentiated carcino-
mas of the endometrium are also rare types. The 
former is characterized by the presence of cells 
with no differentiation, whereas the latter is com-
posed partially by undifferentiated type carci-
noma and by International Federation of 
Gynaecology Obstetrics (FIGO) grade 1 or 2 
endometrioid carcinoma (Kurman et al. 2014).
Mixed carcinomas are made of two or more 
types of endometrial carcinomas, with at least 
one being a type 2 carcinoma (Kurman et al. 
2014).
Neuroendocrine tumors of the endometrium 
are extremely rare tumors.
Table 2 Types of endometrial cancer
Type 1 endometrial cancer
Endometrioid carcinoma (90 %)
Mucinous carcinoma (rarely)
Commonly associated with endometrial hyperplasia
Estrogen-dependent carcinomas
Risk factors:
  Estrogen replacement therapy
  Tamoxifen therapy for breast cancer
  Polycystic ovarian syndrome
  Estrogen producing ovarian tumors
  Obesity (conversion of androgen to estrone in 
adipose tissue)
  Diabetes
  Early menarche and late menopause
  Nulliparity
Usually diagnosed at an early stage
Good prognosis
Type 2 endometrial cancer
Other histological types, namely, serous carcinoma 
and clear-cell carcinoma
Generally develops in a polyp or in an atrophic 
endometrium (serous carcinoma)
May present with distant disease even without 
myometrial invasion (serous carcinoma and clear-cell 
carcinoma)
Usually diagnosed at a high stage
Aggressive clinical behavior
Poor prognosis
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Although they present different pathological 
and epidemiological features, in the latest WHO 
classification they have been grouped under 
endometrial carcinomas (Kurman et al. 2014).
Endometrial neuroendocrine tumors may be 
of low grade (carcinoid tumors) or of high grade 
(small cell neuroendocrine carcinomas and large 
cell neuroendocrine tumors).
The majority of cases reported in the literature 
are of small cell neuroendocrine carcinomas, 
which present as their lung counterpart (Lopes 
Dias et al. 2015).
They tend to be aggressive tumors with a poor 
prognosis. Women are generally in the post-
menopausal age and tend to present with vaginal 
bleeding, but sometimes due to their aggressive-
ness, metastatic pain can be present (Lopes Dias 
et al. 2015; Eichhorn and Young 2001).
Carcinosarcomas are an admixture of carcino-
matous and mesenchymal sarcomatous compo-
nents (Kurman et al. 2014). Carcinomatous 
elements are generally high-grade endometrioid, 
serous, clear-cell, or undifferentiated carcinomas. 
Carcinosarcomas are classified under the “Mixed 
epithelial and mesenchymal” group (Kurman 
et al. 2014). However, due to their carcinomatous 
component and to the fact that their risk factors 
present symptoms and behavior similar to those 
of high-grade endometrial carcinomas, they are 
staged as such.
The radiological and pathological appear-
ances of these tumors tend to differ from the 
other histopathological endometrial cancer sub-
types, as they tend to present as large hemor-
rhagic and necrotic masses that distend the 
endometrial cavity, compressing and frequently 
invading the myometrium and the cervical 
stroma. Their prognosis is poor since they tend to 
present lymphatic and sometimes hematogenous 
spread at the time of diagnosis. Recurrence is 
also frequent.
The majority of endometrial cancers are spo-
radic. Nonetheless, about 5 % of endometrial 
cancers are caused by genetic mutations (e.g., 
Lynch syndrome, Cowden syndrome). These 
cancers tend to occur 10–20 years before the spo-
radic type (Koh et al. 2014; Resnick et al. 2009).
1.3  Symptoms and Diagnosis
About 90 % of patients with endometrial carci-
noma present with abnormal vaginal bleeding 
(Koh et al. 2014; Colombo et al. 2013). Therefore, 
endometrial carcinoma is often diagnosed at an 
early and treatable stage, at which the prognosis 
is good.
Some women also seek care owing to pelvic 
pain or pressure (usually patients with advanced 
stage disease). Moreover, patients may present 
with atypical glandular cells on cervical cytol-
ogy, which requires further evaluation for prema-
lignant or malignant diseases of the endocervix 
and of the endometrium.
The first diagnostic step to evaluate women 
with pre- and postmenopausal abnormal vaginal 
bleeding should be the measurement of endome-
trial thickness with transvaginal ultrasound 
(TVUS) (Fig. 1) (Bennet et al. 2011). 
Transabdominal ultrasound may also be used as 
an adjunct modality, particularly in large leiomy-
omatous uterus or when women cannot tolerate 
TVUS (Bennet et al. 2011).
In postmenopausal women with vaginal bleed-
ing an upper threshold of 5 mm or of 4 mm for 
normal endometrial thickness should be consid-
ered (Bennet et al. 2011; Gull et al. 2003; Karlsson 
et al. 1995; Smith-Bindman et al. 1998). In this 
age group, an endometrial thickness measurement 
Fig. 1 Serous endometrial carcinoma in a 59-year-old 
woman presenting with vaginal bleeding. Transvaginal 
ultrasonography detected thickening of the endometrium 
(arrow), which was posteriorly submitted to biopsy that 
diagnosed a serous endometrial carcinoma
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≤5 mm is associated with the absence of endome-
trial cancer (Gupta et al. 2002). This cut-off value 
should also be used in women under hormone 
replacement therapy and under tamoxifen (Bennet 
et al. 2011).
In symptomatic patients in premenopausal age, 
an upper threshold of normal endometrial thick-
ness is more difficult to establish due to its varia-
tions during the menstrual cycle. In this group of 
women, the assessment of the endometrium should 
be performed during the early first half of the men-
strual cycle (Bennet et al. 2011). In these women, 
an endometrial thickness >16 mm has shown to 
have a sensitivity of 67 % and a specificity of 75 % 
for detecting endometrial abnormalities (Bennet 
et al. 2011; Hulka et al. 1994). A heterogeneous 
endometrium or an area of focal thickness should 
be also further investigated (Bennet et al. 2011; 
Goldstein et al. 2001).
If the endometrium is thickened or heteroge-
neous, a sample of the endometrium must be 
undertaken to establish a definite histopathologi-
cal diagnosis. In these cases a hysteroscopy with 
biopsy or resection should be performed.
Before treatment, the initial evaluation should 
include a medical history, a physical and gyneco-
logical examination, a complete blood count, and 
a chest radiograph (Koh et al. 2014).
If the age of the onset of the disease is 
<50 years and if there is history of familiar 
colorectal or endometrial cancer, screening for 
genetic mutations should be performed (Koh 
et al. 2014).
Women with Lynch syndrome, without endo-
metrial cancer, should be screened annually with 
an endometrial biopsy (Koh et al. 2014; Järvinen 
et al. 2009; Meyer et al. 2009). Prophylactic hys-
terectomy with bilateral salpingoophorectomy 
may be considered in these patients (Koh et al. 
2014; Schmeler et al. 2006).
2  Endometrial Cancer Staging
Endometrial carcinoma is staged with the 
International Federation of Gynaecology 
Obstetrics (FIGO) system, which was last revised 
in 2009 (Table 3) (Creasman 2009; Pecorelli 
2009). This classification defines that endome-
trial carcinoma is staged on the basis of surgico- 
pathological findings.
The complete surgical staging procedure 
implies hysterectomy with bilateral salpingo- 
oophorectomy, assessment of the abdominal cav-
ity with biopsies of suspicious peritoneal lesions, 
cytology of peritoneal washings, and pelvic and 
retroperitoneal lymphadenectomy (Koh et al. 
2014). In patients with serous carcinoma, clear- 
cell carcinoma, and carcinosarcoma, the surgical 
staging procedure should be the same as for ovar-
ian cancer (Koh et al. 2014).
The FIGO 2009 staging classification is as fol-
lows (Table 3) (Pecorelli 2009):
In stage I, the tumor is confined to the uterus. 
This stage is subdivided in two substages: 
stage IA (the tumor invades <50 % of the myo-
metrium) and stage IB (the tumor invades ≥50 % 
of the myometrium).
Table 3 Endometrial Cancer Staging: FIGOa 2009
Stage I—The tumor is confined to the uterine corpus
IA—Absence or invasion of <50 % of the 
myometrium
IB—Invasion of ≥50 % of the myometrium
Stage II—The tumor invades the cervical stroma, but 
not beyond the uterus
Stage III—There is local or regional involvement
IIIA—The tumor invades the serosa and/or the adnexa
IIIB—Presence of vaginal and/or parametrial 
involvement
IIIC—Presence of pelvic or para-aortic 
lymphadenopathies
  IIIC1—Presence of pelvic lymphadenopathies
  IIIC2—Presence of para-aortic lymphadenopathies, 
with or without pelvic lymphadenopathies
Stage IV—The tumor invades the bladder mucosa and/
or the intestinal mucosa, and/or there are distant 
metastases
IVA—The tumor invades the bladder mucosa and/or 
the intestinal mucosa
IVB—Presence of distant metastases, including 
abdominal metastases and/or inguinal 
lymphadenopathies.
Adapted from Pecorelli (2009)
aFIGO International Federation of Gynaecology and 
Obstetrics
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In stage II, the tumor invades the cervical 
stroma, but not beyond the uterus.
Stage III is subdivided into three substages. In 
stage IIIA, the tumor invades the serosa or/and 
the adnexa (direct extension or metastasis). In 
stage IIIB, there is involvement of the parametria 
and/or the vagina (direct extension or metasta-
sis). In stage IIIC, there is lymph node involve-
ment (IIIC1 if there are positive pelvic lymph 
nodes and IIIC2 if there are positive para-aortic 
lymph nodes).
Stage IV is also subdivided into two sub-
stages. The tumor is in stage IVA if there is 
mucosal invasion of the bladder or/and the bowel 
and it is in stage IVB if there are distant metasta-
sis including abdominal metastasis and/or the 
presence of positive inguinal lymph nodes.
MR imaging is not considered in the FIGO 
staging of endometrial carcinoma, but due to its 
high contrast resolution and reproducibility, it 
has an important role in the preoperative staging 
of the disease. Thus, it is crucial for tailoring the 
surgical approach to these patients.
There is still no consensus on whether com-
plete surgical staging with primary pelvic and 
para-aortic lymphadenopathy should be performed 
at stage I, namely, in patients with low recurrence 
risk (Bonatti et al. 2015; Todo et al. 2010; May 
et al. 2010). However, it is known that the tumor 
histological type and grade, the presence of myo-
metrial invasion ≥50 %, and the presence of lym-
phovascular space invasion correlate with the 
presence of lymph node metastasis and with over-
all survival (Rechichi et al. 2010; Sala et al. 2013; 
Boronow 1990; Larson et al. 1996). From these 
features, only the histological type and grade can 
be assessed preoperatively without imaging. 
Nonetheless, discrepancies of up to 15 % between 
the pre- and postoperative tumoral histopathologi-
cal results have been described (Sala et al. 2013; 
Frei et al. 2000).
MR can accurately determine the depth of 
myometrial invasion. Therefore, in conjunction 
with the histopathological grade it may be used to 
select the patients that might be candidates for 
pelvic and para-aortic lymphadenectomy, pre-
cluding surgery in low-risk patients, thus avoid-
ing the morbidities associated with this procedure. 
Presence of lymph node metastases has been 
reported in more than 30 % of the cases of endo-
metrial cancer with ≥50 % of myometrial inva-
sion and in only 5 % of cases when the tumor 
invades <50 % of the myometrium (Larson et al. 
1996; Gallego et al. 2014).
Lymphovascular invasion is generally assessed 
postoperatively. It is related not only to the likeli-
hood of lymph node involvement, but with tumor 
relapse and poor survival (Sala et al. 2013; Fujii 
et al. 2015; Briët et al. 2005). Not many studies 
have addressed the role of MR in diagnosing 
lymphovascular space involvement. However, a 
study by Nougaret et al. showed that whole tumor 
volume and ADC could be useful in its prediction 
(Nougaret et al. 2015).
Cervical stromal invasion is also associated 
with lymph node metastasis and poor survival. 
MR can accurately diagnose cervical stromal 
invasion and parametrial invasion. This is partic-
ularly important so surgeons can avoid cutting 
through the tumor and thus perform an extensive 
resection (Sala et al. 2013).
Moreover, MR is helpful is diagnosing 
advanced disease involving the adnexa and the 
peritoneum, which generally are contraindica-
tions to laparoscopic and robotic surgery (Sala 
et al. 2013; Venkat et al. 2012; Amant et al. 
2007). Other extra-uterine coexistent pathologies 
can also be diagnosed that may help determining 
the surgical approach.
Therefore, MR is useful not only in planning 
surgical treatment but also in selecting more 
advanced and difficult surgical cases that should 
be guided to specialized oncologic centers.
MR is also useful in determining the origin 
(cervical or endometrial) of a biopsy proven adeno-
carcinoma (Fig. 2). Vargas and colleagues showed 
that by assessing the epicenter of the tumor, the 
endometrial versus the cervical origin of an adeno-
carcinoma could be determined with an accuracy of 
85–88 % (Vargas et al. 2011). Furthermore, endo-
metrial thickening, expansion of the endometrial 
cavity by a mass, and the presence of a tumor invad-
ing the myometrium may aid the discrimination 
between these two types of tumors (Haider et al. 
2006). This distinction is particularly important, 
because early stage cervical adenocarcinomas are 
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treated with surgery, advanced stage cervical adeno-
carcinomas are treated with chemotherapy and 
radiotherapy and endometrial carcinomas are 
treated primarily with surgery.
Although fertility-sparing progesterone ther-
apy is not the standard of care for endometrial 
cancers, it might be considered according to 
patients request in treatment of low-grade endo-
metrial cancers that do not invade the myome-
trium. In these cases, MR is essential in defining 
which patients are candidates to this approach.
2.1  MR Protocol for Staging 
Endometrial Carcinoma
In our institution the MR protocol for staging 
endometrial carcinoma is as follows (Table 4):
Patients are advised to fast 4–6 h before the 
procedure. A fast acting laxative enema to clean 
the bowel is administered the day before the 
exam and during the morning of the exam. 
Patients are encouraged to void before the exami-
nation since a full bladder degrades the quality of 
T2-weighted images.
In order to reduce bowel peristalsis and hence 
improve image quality, 1 mg of glucagon intrave-
nous is administered before the exam. Alternatively, 
20 mg or 40 mg of hyoscine butylbromide intra-
muscular/intravenous can be administered.
Patients are advised to avoid the use of vaginal 
tampon.
MR imaging can either be performed in a 
1.5 T or a 3 T MR machine. 3 T MR has been not 
shown to offer significant benefit over 1.5 T MR 
in the evaluation of endometrial cancer, since 3 T 
MR is more prone to susceptibility and chemical- 
shift artifacts that impair the image quality 
(Wakefield et al. 2013; Haldorsen and Salvesen 
2012; Hori et al. 2013).
Fig. 2 Endometrial carcinoma that invades the cervical 
stroma in a 53-year-old woman. Sagittal T2-weighted 
image. Distinction between endometrial and cervical ori-
gin of an adenocarcinoma may be challenging. Radiologists 
should look for the epicenter of the tumor (>50 %) (circle), 
and other signs that may help defining endometrial origin, 
such as endometrial thickness (arrow), expansion of the 
uterine cavity by a mass (squared brackets), and invasion 
of the myometrium (dashed arrow)
Table 4 MR protocol scheme for endometrial cancer 
staging
MRI protocol for endometrial cancer staging
Abdomen
  T2 FSE axial (6 mm/1 mm)—from the diaphragm 
to the iliac crests
  Axial DWI and the respective ADC maps (6 mm)
Pelvis
  T1 FSE axial (5 mm/0.5 mm)
  T2 FSE axial (5 mm/0.5 mm); T2 FSE sagittal 
(4 mm/0.4 mm); T2 FSE axial oblique of the uterine 
corpus (perpendicular to the uterine cavity; 
4 mm/0.4 mm)
  Dynamic contrast-enhanced study in the axial 
oblique plane of the uterine corpus: 3D T1, FS 
pre- and postcontrast administration, five 
acquisition phases (until 150 s; 2 mm)
  Axial DWI and the respective ADC maps 
(5 mm/0.5 mm)
Protocol variants
If there is suspicion of cervix invasion:
  T2 FSE axial oblique of the uterine cervix 
(perpendicular to the cervical canal; 4 mm/0.4 mm)
  Dynamic contrast-enhanced study in the sagittal 
plane: 3D T1, FS pre- and postcontrast 
administration, five acquisition phases (until 150 s; 
2 mm)
  Axial oblique plane of the uterine cervix 
postcontrast injection 3D T1, FS in late phase 
(4 min; 2 mm)
Endometrial Cancer
A pelvic phase array is used along with ante-
rior and superior saturation bands.
The patient should be placed in a supine posi-
tion for the whole exam. However, prone position 
may be used in uncooperative patients.
Axial imaging of the abdomen (from 
 diaphragm to iliac crests) should be per-
formed for the evaluation of advanced 
disease, with fast recovery, fast spin-echo T2- 
weighted images (6 mm/1 mm, breath-hold). Abdo-
minal axial diffusion- weighted images (DWI) 
(6 mm, b- values—0, 500,  1000 s/mm2) and the 
respective ADC maps should also be obtained.
Evaluation of the pelvis should be performed 
with axial fast spin-echo T1-weighted images 
(5 mm/0.5 mm), axial fast spin-echo T2-weighted 
images (5 mm/0.5 mm), and sagittal fast spin- 
echo T2-weighted images (4 mm/0.4 mm).
Fast spin-echo T2-weighted axial oblique 
images (perpendicular to the uterine cavity, 
4 mm/0.4 mm) are helpful in assessing myome-
trial invasion (Fig. 3).
a c
b d
Fig. 3 (a, b) Axial oblique plane of the uterine corpus (perpendicular to the uterine cavity); (c, d) axial oblique plane 
of the uterine cervix (perpendicular to the cervical canal)
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The dynamic contrast-enhanced MR images 
are obtained after the injection of 0.1 mmol/kg of 
gadolinium at a rate of 2 mL/s. In our institution, 
images are acquired using a 3D-recalled echo fat-
suppressed T1-weighted sequence, pre- and post-
contrast injection during five acquisition phases 
in the axial-oblique plane (perpendicular to the 
uterine cavity), until 150 s (2 mm). The dynamic 
study tends to be avoided in patients with renal 
impairment.
DWI study (b-values—0, 600, 1000 s/mm2, 
5 mm/0.5 mm) and the respective ADC maps are 
performed in the axial plane.
If there is suspicion of cervix invasion, axial 
oblique of the cervix fast spin-echo T2-weighted 
images (perpendicular to the cervical canal, 
4 mm/0.4 mm) are obtained to evaluate parame-
trial invasion (Fig. 3). In these cases, the dynamic 
study should be performed in the sagittal plane 
using a 3D-reccaled echo fat-suppressed 
T1-weighted sequence, pre- and postcontrast 
injection during five acquisition phases until 
150 s (2 mm). Furthermore, axial oblique of the 
cervix (perpendicular to cervical canal) postcon-
trast injection 3D-reccaled echo fat-suppressed 
T1-weighted images are obtained in a late phase 
(4 min, 2 mm), to better assess cervical stromal 
invasion (Fig. 3).
2.2  MR Findings According 
to the Stage of Endometrial 
Carcinoma
On conventional imaging, the normal uterus 
anatomy is better depicted on T2-weighted 
images. The endometrium tends to be hyperin-
tense, the junctional zone is hypointense and the 
outer myometrium shows intermediate intensity 
(Fig. 4).
Endometrial cancer is isointense to the endo-
metrium on T1-weighted images and it most fre-
quently shows heterogeneous moderate to 
high-signal intensity on T2-weighted images. 
However, it can also show low-signal intensity on 
T2-weighted images (Fig. 5).
On DCE-MR, in the arterial phase (≈30 s) 
endometrial tumors enhance earlier than does the 
normal endometrium, as this is the most adequate 
sequence to depict small endometrial tumors 
confined to the endometrium. At the equilibrium 
phase (≈120–180 s), tumors tend to be hypoin-
tense relative to the myometrium. However, they 
can remain isointense and a minority can even be 
hyperintense (Figs. 5 and 6).
On DWI-MR the tumors usually show 
restricted diffusion (hyperintensity on high 
b-value sequences and hypointensity on the 
respective ADC map) (Fig. 6). ADC values have 
shown to be significantly lower in endometrial 
carcinoma than in normal endometrium and 
benign conditions such as endometrial polyps 
and submucosal leiomyomas (Fujii et al. 2008; 
Tamai et al. 2007; Takeuchi et al. 2009; Rechichi 
et al. 2011) (Fig. 7).Therefore, this functional 
sequence can be helpful in diagnosing an endo-
metrial tumor when biopsy cannot be easily per-
formed (i.e., in the case of cervical stenosis) or 
when the histopathological diagnosis is not con-
clusive. Cross-reference with conventional 
sequences is, however, mandatory to avoid pit-
falls, since restricted diffusion may be present 
also in retained secretions in the endometrial 
cavity.
Several studies have shown that there is no 
relation between the tumor grade, aggressive-
ness, and ADC values (Rechichi et al. 2011; 
Fig. 4 Normal uterine T2-weighted anatomy. Sagittal 
T2-weighted image. Hyperintense endometrium (arrow); 
hypointense junctional zone (dashed arrow); outer myo-
metrium showing intermediate intensity (dotted line); 
hypointense cervical stroma (arrowhead)
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Bharwani et al. 2011). However, in one study 
higher grade tumors were associated with lower 
ADC values but there was a considerable over-
lap in estimation of histological grade based on 
ADC values (Tamai et al. 2007). Moreover, 
high ADC values may be found in high-grade 
tumors with a large necrotic component (Sala 
et al. 2010).
2.2.1  Stage I Disease
Stage I endometrial carcinomas account for 
approximately 74 % of endometrial cancers 
(Cancer Incidence Statistics 2015). The most 
important role of the radiologist, when facing a 
stage I endometrial cancer is to determine the 
extent of myometrial invasion, since stage I dis-
ease is subdivided into stage IA disease, if the 
a b
c d
Fig. 5 MR features of endometrial cancer. (a) endometri-
oid cancer showing heterogeneous high-signal intensity 
on sagittal T2-weighted image (arrow); (b) endometrioid 
cancer showing hyposignal intensity on axial oblique 
T2-weighted image, a less common appearance (dashed 
arrow); (c, d) endometrioid cancer distending the uterine 
cavity and compressing the myometrium showing a 
remarkable heterogeneous high-signal intensity on axial 
oblique T2 weighted image (dotted arrows) and mixed 
hypointensity and isointensity relative to outer myome-
trium after administration of gadolinium in the equilib-
rium phase (dotted arrows)
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tumor only invades <50 % of the myometrium, 
and stage IB disease, if the tumor invades ≥50 % 
of the myometrium (Figs. 8 and 9) (Pecorelli 
2009). If the patient is considering fertility- sparing 
treatment, it is also important to clearly define if 
the tumor is confined to the endometrium or if it 
invades the superficial myometrium, which pre-
cludes this approach (Fig. 10) (Jafari Shobeiri 
et al. 2013; Kesterson and Fanning 2012).
T2-weighted images are useful in determining 
myometrial invasion. A focal or diffuse thicken-
ing of the endometrium with a clearly visualized 
intact junctional zone is a sign that the tumor is 
confined to the endometrium (Fig. 8). Breaching 
and irregularity of the hypointense signal of the 
junctional zone implies superficial myometrial 
invasion (Manfredi et al. 2005).
The depth of myometrial invasion should be 
based on the thickness of remaining myometrium 
where the tumor is at its deepest point into the 
myometrium (Haldorsen and Salvesen 2012; 
Koyama et al. 2007).
However, there are situations where the evalua-
tion of myometrial invasion by T2-weighted 
images may be difficult or even impossible, such 
as the presence of: a tumor in the cornua (Fig. 11); 
a fibromatous uterus (Fig. 11); a less conspicuous 
junctional zone in postmenopausal women (Fig. 
12); a thinned myometrium in postmenopausal 
women (Fig. 13); an adenomyotic uterus (Fig. 14); 
a polypoid uterus; a congenital abnormality (Fig. 
15); and the presence of poor tumor signal differ-
ence/isointensity between the tumor and the myo-
metrium (Figs. 6 and 16) (Kinkel 2006; Scoutt 
et al. 1995; Yamashita et al. 1993a; Saez et al. 
2000; Fanning et al. 1990). In these cases, 
DCE-MR and DWI-MR play an important role, 
when combined with T2-weighted images.
a b
c
Fig. 6 (a) Endometrioid carcinoma in a 79-year-old 
woman, isointense to the myometrium after administra-
tion of gadolinium in the equilibrium phase, making it dif-
ficult to access the depth of myometrial invasion (arrow); 
(b, c) diffusion-weighted image (b = 1000 mm/s2) and the 
respective ADC map show typical tumoral restricted dif-
fusion, enabling the radiologist to diagnose invasion of 
≥50 % the myometrium (stage IB) (arrow)
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On DCE-MR imaging, in the arterial phase 
(≈ 30 s), the junctional zone typically enhances 
avidly when compared to the endometrial tumor 
(Manfredi et al. 2005). Disruption of this suben-
dometrial enhancement usually indicates myo-
metrial invasion (Fujii et al. 2015; Manfredi et al. 
2005; Nakao et al. 2006; Yamashita et al. 1993b; 
Kaneda et al. 2011; Frei and Kinker 2001). This 
is particularly important when the patient is being 
considered for fertility-sparing treatment since 
the FIGO 2009 division of stage I disease is only 
based on the presence of invasion of the inner or 
outer portions of the myometrium (Fig. 10) 
(Jafari Shobeiri et al. 2013; Kesterson and 
Fanning 2012).
On the other hand, it is in the equilibrium 
phase (≈120 s) that is better diagnosed deep myo-
metrial invasion. In this phase there is more pro-
nounced contrast-to-noise ratio between the outer 
myometrium, which is markedly hyperintense, 
and the endometrial tumor, which is usually 
hypointense (Figs. 9, 13 and 15) (Manfredi et al. 
2005). Attention must be paid to the presence of 
peritumoral inflammatory enhancement, which 
a b
c d
Fig. 7 Benign polyp in a 60-year-old woman. (a) Axial 
oblique T2-weighted image shows a heterogeneous 
hyperintense filling of the endometrial cavity; (b) axial 
oblique 3D fat-suppressed T1-weighted sequence after 
the administration of gadolinium in the arterial phase 
(30 s) shows lesional heterogeneous enhancement (arrow). 
Note the avid enhancement of the junctional zone in this 
phase when compared to the outer myometrium (dashed 
arrow). Both T2 and DCE-MR characteristics of this 
benign polyp mimic those of endometrial carcinoma; (c) 
axial diffusion-weighted image (b = 1000 s/mm2) shows 
high-signal intensity of the tumor; (d) the apparent diffu-
sion coefficient map also shows high-signal intensity. In 
contrast to what would be expected in an endometrial car-
cinoma, this benign polyp does not show restricted 
diffusion
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can exaggerate the appearance of myometrial 
invasion (Sala et al. 2013).
DWI-MR has shown to be very useful in 
assessing myometrial invasion, especially in 
patients who cannot receive intravenous contrast, 
in patients with isointense or hyperintense tumors 
relative to the myometrium following contrast 
administration, and in patients with adenomyosis 
(Figs. 16, 14 and 16) (Takeuchi et al. 2009; Sala 
et al. 2010).
Moreover, DWI-MR is very accurate in 
assessing myometrial invasion.
a b
Fig. 8 Stage IA endometrioid carcinoma. (a) Axial 
oblique T2-weighted image; (b) axial oblique 3D fat- 
suppressed T1-weighted sequence after the administration 
of gadolinium in the arterial phase (30 s). There is preser-
vation of the regular hypointense signal on T2-weighted 
image and of the regular enhancement of the junctional 
zone after administration of gadolinium in the arterial 
phase (dashed arrow), thus the tumor is confined to the 
endometrial cavity (arrow). Note the intramural leiomy-
oma in the posterior corpus (dotted arrow)
a b
Fig. 9 Stage IB endometrioid carcinoma in an 85-year- 
old woman. (a) Axial oblique T2-weighted image; (b) 
axial oblique 3D fat-suppressed T1-weighted sequence 
after the administration of gadolinium in the equilibrium 
phase (120 s). There is extension of the tumor to the outer 
portion of the left posterior myometrium (arrow), which 
is clearly depicted after the administration of gadolinium 
in the equilibrium phase, where there is more pronounced 
contrast-to-noise ratio between the hypointense tumor and 
the hyperintense outer myometrium
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Fig. 10 Endometrioid carcinoma in a woman considering 
fertility-sparing therapy. (a) Axial oblique T2-weighted 
image; (b) axial oblique 3D fat-suppressed T1-weighted 
sequence after the administration of gadolinium in the 
arterial phase (30 s). Axial oblique T2-weighted image is 
inconclusive regarding myometrial invasion, whereas 
DCE-MR in the arterial phase clearly shows that there is 
no disruption of the junctional zone enhancement and 
therefore the tumor does not invade the myometrium
a
f g h i
j k
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Fig. 12 Stage IA mucinous carcinoma of the endometrium 
in a 72-year-old woman with a thinned junctional zone. (a) 
Sagittal T2-weighted image; (b) axial oblique T2-weighted 
image; (c) axial oblique 3D fat-suppressed T1-weighted 
sequence after the administration of gadolinium in the arte-
rial phase (30 s). The junctional zone of this postmeno-
pausal woman cannot be identified in T2-weighted images, 
making it difficult to assess the depth of tumoral myome-
trial invasion. The use of T2-weighted images alone might 
suggest that the tumor invades the outer portion of the myo-
metrium (arrow). However contrast-enhanced image in the 
arterial phase clearly shows an enhancing regular junctional 
zone (dashed arrow) and the tumor confined to the endo-
metrial cavity (dotted arrow)
a b c
Fig. 13 Stage IA endometrioid carcinoma in a 72-year- old 
woman with myometrial thinning secondary to stretching 
due to a large tumor. (a) Sagittal T2-weighted image; (b) 
axial T2-weighted image; (c) axial oblique 3D fat-sup-
pressed T1-weighted sequence after the administration of 
gadolinium in the equilibrium phase (120 s). Distortion at 
the base of this polypoid tumor is difficult to distinguish 
from outer myometrial tumoral invasion on T2 weighted 
images (arrow). Contrast-enhanced image in the equilib-
rium phase clearly shows a hypointense tumor (dashed 
arrow) that does not invade the outer hyperintense myome-
trium (dotted arrow). Note the T2 hypointense intramural 
leiomyoma (asterisk)
Fig. 11 Endometrial adenocarcinoma in a 71-year-old 
patient, previously submitted to radiation therapy due to 
cervical cancer. (a–e) Sagittal T2-weighted images fail to 
clearly show a small isointense tumor in the right uterine 
cornua (yellow arrow), due to the coexistence of submu-
cosal leiomyomas (dotted arrow); (f–i) axial oblique 
T2-weighted images better depict this isointense lesion 
and clearly differentiate it from the hypointense leiomyo-
mas; (j) axial diffusion-weighted image (b = 1000 s/mm2) 
shows high-signal intensity of the tumor; (k) the apparent 
diffusion coefficient map shows hyposignal intensity, 
therefore tumoral restricted diffusion. In contrast, the leio-
myoma present in the left cornua, does not show restricted 
diffusion
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Fig. 14 Endometrioid carcinoma in a 71-year-old 
woman with an adenomyotic uterus. (a) Axial oblique 
T2-weighted image. (b) Axial oblique 3D fat-sup-
pressed T1-weighted sequence after the administration 
of gadolinium in the equilibrium phase (120 s). The 
presence of posterior adenomyosis (dashed arrow) 
impedes the assessment of tumoral (arrow) myometrial 
invasion on both T2-weighted image and contrast-
enhanced image. Diffusion-weighted images could be 
useful in this case
a b
c d
Fig. 15 Stage IB endometrioid carcinoma in a 76-year- 
old woman with a bicornuate bicollis uterus. (a) Axial 
T2-weighted image; (b) axial oblique 3D fat-suppressed 
T1-weighted sequence after the administration of gado-
linium in the equilibrium phase (120 s); (c) axial diffusion- 
weighted image (b = 1000 s/mm2). (d) ADC map. In this 
bicornuate bicollis uterus, the tumoral invasion of the 
anterior outer myometrium is difficult to depict on both 
T2-weighted image and after administration of contrast. 
Diffusion-weighted image and the respective ADC map 
clearly identify a focal area of restricted diffusion in the 
anterior outer myometrium, staging the tumor as IB
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Recent studies have shown that DWI-MR is 
significantly superior in the assessment of myo-
metrial invasion when compared to DCE-MR 
(Bonatti et al. 2015; Rechichi et al. 2010; 
Takeuchi et al. 2009; Beddy et al. 2012).
A prospective study conducted by Rechichi et al. 
has concluded that DWI-MR is highly accurate in 
assessing the depth of myometrial invasion and per-
haps it could replace DCE-MR as a complement to 
T2-weighted images in the preoperative evaluation 
of endometrial carcinoma (Rechichi et al. 2010). 
These findings were also supported by the study of 
Bonatti et al. that also stated that T2-weighted 
images and DWI could replace the combination of 
T2-weighted images and contrast-enhanced 
T1-weighted images in the preoperative staging of 
endometrial carcinoma (Bonatti et al. 2015).
Takeuchi and coworkers also reported an 
accuracy of 94 % for DWI and of 88 % for 
DCE-MR in the assessment of myometrial inva-
sion (Takeuchi et al. 2009).
ADC maps have also shown to provide accu-
rate measurement of the depth of myometrial 
invasion (Gallego et al. 2014).
Nonetheless, a recent meta-analysis assessing 
only nine studies showed that although DWI-MR 
has a slightly higher specificity in the diagnosis 
of myometrial invasion, DCE-MR and DWI-MR 
do not differ significantly in sensitivity and speci-
ficity in presurgical diagnosis of myometrial 
invasion (Andreano et al. 2014).
2.2.2  Stage II Disease
Stage II disease is characterized by cervical stro-
mal invasion (Pecorelli 2009).
In the majority of cases, T2-weighted images 
are helpful in diagnosing cervical stromal inva-
sion by depicting a heterogeneous hyperintense 
tumor disrupting the hypointense cervical stroma 
(Manfredi et al. 2005).
Axial oblique plane of the cervix (per-
pendicular to the cervical canal) postcontrast 
injection 3D-reccaled echo fat-suppressed 
T1-weighted images in a late phase (≈80–
240 s) are also very useful in assessing cervical 
stromal invasion, as they show the disruption 
of cervical enhancement by the tumor (Fig. 17) 
(Tirumani et al. 2013; Haldorsen and Salvesen 
a b
c d
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Fig. 16 Stage IB polypoid endometrioid carcinoma that 
distends the uterine cavity and causes myometrial thinning 
in a 68 year-old woman. (a) Axial T2-weighted image; (b) 
axial oblique 3D fat-suppressed T1-weighted sequence after 
the administration of gadolinium in the equilibrium phase 
(120 s); (c) axial diffusion-weighted image (b = 1000 s/
mm2); (d) ADC map; (e) sagittal T2-weighted image. The 
endometrial tumor is heterogeneous and shows both areas of 
hypointense and hyperintense signal relatively to the outer 
myometrium after administration of gadolinium in the equi-
librium phase. This makes it difficult to assess myometrial 
invasion. Outer tumoral myometrial invasion in this thinned 
myometrium is better depicted in the diffusion-weighted 
image and in the respective ADC map (arrows)
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2012; Seki et al. 2000). Normal enhance-
ment of the cervical epithelium is present in 
tumors that project into the endocervical canal 
but do not invade the cervical stroma (Fig. 18) 
(Tirumani et al. 2013; Haldorsen and Salvesen 
2012).
a b
Fig. 17 Stage II endometrioid carcinoma in an 83-year- 
old woman (a) sagittal T2-weighted image; (b) axial 
oblique plane of the cervix (perpendicular to the cervical 
canal) postcontrast injection 3D-reccaled echo fat- 
suppressed T1-weighted images in a late phase (4 min). 
Sagittal T2-weighted image shows a voluminous endome-
trial tumor that prolapses in the cervical canal. The axial 
oblique plane of the cervix is very useful in detecting stro-
mal invasion, especially after the administration of gado-
linium in a late phase (4 min) (arrow)
a b c
Fig. 18 Endometrial cancer prolapsed into the endocervi-
cal canal (a) Axial oblique plane of the cervix (perpen-
dicular to the cervical canal) T2-weighted image: (b) 
sagittal T2-weighted image; (c) sagittal postcontrast 
injection 3D-reccaled echo fat-suppressed T1-weighted 
images in the equilibrium phase (120 s). Both axial 
oblique and sagittal T2-weighted images raise the suspi-
cion of cervical invasion. However, there is normal 
enhancement of the cervical epithelium without any dis-
ruption, which excludes stage II disease
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2.2.3  Stage III Disease
Stage III disease is defined by local or regional 
spread of the tumor and it is subdivided into three 
substages (Pecorelli 2009).
In stage IIIA endometrial cancer, the tumor 
invades the serosa or/and the adnexa (Figs. 19 
and 20).
Disruption of the serosal hypointense signal 
on T2-weighted images or loss of the enhancing 
myometrial outer margin on DCE-MR indicates 
serosal invasion (Fig. 19) (Tirumani et al. 2013; 
Manfredi et al. 2005).
The invasion of the ovaries may be due to 
direct extension via transmyometrial invasion or 
due to metastasis. Nodular foci in the adnexa are 
particularly frequent in type II endometrial can-
cer and in high-grade endometrioid carcinoma 
(Tirumani et al. 2013). DWI-MR is very useful in 
depicting these cases as well as pelvic peritoneal 
disease (Fig. 20) (Tirumani et al. 2013; Sala et al. 
2010; Shen et al. 2008).
In stage IIIB disease, there is tumoral involve-
ment of the parametria and/or the vagina by direct 
extension or by skip metastasis (Figs. 21, 22 and 
23) (Pecorelli 2009). Images of the axial oblique 
plane of the cervix (perpendicular to the cervical 
canal) are very helpful in detecting parametrial 
invasion (Fig. 21). Detection of parametrial inva-
sion is particularly important so surgeons can avoid 
perform a simple hysterectomy and thus perform a 
more extensive resection (Sala et al. 2013).
In stage IIIC endometrial cancer there is lymph 
node involvement (IIIC1 if there are positive pelvic 
lymph nodes and IIIC2 if there are positive para-
aortic lymph nodes) (Fig. 24) (Pecorelli 2009).
MR sensitivity for detecting tumoral lymph 
node involvement is mostly low (Haldorsen and 
Salvesen 2012). The assessment of lymphade-
nopathies on MR imaging is still based on mor-
phologic criteria (shortest axis diameter 
>10 mm) (Haldorsen and Salvesen 2012; 
Manfredi et al. 2004). DWI-MR helps detect 
lymph nodes, but there is a significant overlap 
with the ADC values of benign and malignant 
nodes (Nougaret et al. 2013; Nakai et al. 2008; 
Roy et al. 2010).
2.2.4  Stage IV Disease
Stage IV endometrial cancers are subdivided in 
two substages: stage IVA if there is invasion of 
Fig. 19 Stage IIIA endometrioid carcinoma. (a) Axial 
oblique T2-weighted image shows disruption of the T2 
hypointense serosal signal (dashed arrow) and tumoral 
invasion of the left ovary (arrow)
a b c
Fig. 20 Stage IIIA endometrioid carcinoma with subtle 
peritoneal nodules (a) axial T2-weighted image; (b) axial 
diffusion-weighted image (b = 1000 s/mm2); (c) ADC 
map. Subtle peritoneal implants can be better depicted 
with diffusion-weighted images (arrow)
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the bladder or/and the bowel (Figs. 25 and 26); 
stage IVB if there are distant metastasis includ-
ing abdominal metastasis and/or the presence of 
positive inguinal lymph nodes or/and para-aortic 
nodes above the renal hila (Fig. 27) (Pecorelli 
2009).
For an endometrial tumor to be considered as 
stage IVA, a lesion transgressing the hypoin-
tense T2-signal of the muscularis propria of the 
bladder and/or of the bowel must be clearly 
seen, as well as disrupting the hyperintense sig-
nal of the mucosa (Figs. 25 and 26) (Tirumani 
et al. 2013). Moreover, tumoral enhancement 
within the lumen should also be present (Figs. 
25 and 26). This is particularly important in the 
differential diagnosis of bladder bullous edema 
(a sign of tumoral involvement of the bladder 
serosa and muscular layer, but not of the 
mucosa), since it is not considered stage IVA 
disease (Sala et al. 2013).
Although rare at presentation, distant hema-
togenous disease most commonly affects the 
liver, lungs, and bone (Fig. 27) (Numazaki et al. 
2009).
In type 2 endometrial cancer, and in high-
grade endometrioid endometrial cancer, stage 
IVB  disease may present as in ovarian cancers 
with peritoneal carcinomatosis (Tirumani et al. 
2013; Sala et al. 2013).
a b
Fig. 21 Stage IIIB endometrioid carcinoma (a) sagittal 
T2-weighted image; (b) axial oblique plane of the cervix 
(perpendicular to the cervical canal) T2-weighted image. 
Parametrial invasion can be better depicted in the axial 
oblique plane of the cervix, where disruption of the 
hypointense stromal signal can be seen as well as tumor 
extending to both parametria (arrows)
Fig. 22 Stage IIIB endometrioid carcinoma. (a) Sagittal 
T2-weighted image shows disruption of the T2 hypoin-
tense vaginal signal with invasion of the inferior third of 
the vagina (arrows)
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3  Recent Advances 
in Functional MR Imaging 
in Assessing Endometrial 
Carcinoma
In perfusion MR, repeated acquisitions of 
sequential images during the passage of gadolin-
ium through the tumor are performed. Tumoral 
signal intensity versus time graphs and quantita-
tive perfusion maps may be obtained, making it 
possible to evaluate microvascularity parameters 
(Haldorsen and Salvesen 2012). The value of per-
fusion MR in assessing endometrial cancer is not 
yet established and validation studies are neces-
sary to study its potential benefit.
Haldorsen et al. suggested that DCE-MRI 
may offer new information about the histological 
subtype and clinical course of endometrial carci-
noma (Haldorsen et al. 2013). On the other hand, 
other studies regarding DCE-perfusion MR and 
tumor grading have shown contradictory results 
(Haldorsen et al. 2013; Ippolito et al. 2014a, b).
a b
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Fig. 23 Stage IIIB endometrioid carcinoma in a 62-year- 
old woman with skip vaginal metastasis. (a) Sagittal 
T2-weighted image; (b) axial T2-weighted image; (c) 
axial diffusion-weighted image (b = 1000 s/mm2); (d) 
ADC map. In the anterior lower third of the vagina a small 
lesion showing restricted diffusion can be seen (arrow). It 
was diagnosed as a vaginal metastasis
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Fig. 24 Stage IIIC endometrial cancer (a) axial 
T2-weighted image shows pelvic lymphadenopathies 
(arrows) (stage IIIC1 disease); (b) axial T2-weighted 
image shows para-aortic lymphadenopathies (dashed 
arrows) (Stage IIIC2 disease)
a
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Fig. 25 Stage IVA endometrioid carcinoma that invades 
the sigmoid colon in a 75-year-old woman. (a) Sagittal 
T2-weighted image; (b) sagittal 3D fat-suppressed 
T1-weighted sequence after the administration of gado-
linium in the equilibrium phase (120–180 s); (c) axial 
T2-weighted image; (d) axial diffusion-weighted image 
(b = 1000 s/mm2); (e) ADC map. T2-weighted images 
show disruption of the hypointense signal of the sigmoid 
colon wall and mucosal invasion. There is tumoral 
enhancement within the lumen. The tumor shows also 
marked restricted diffusion, which can also be seen in the 
sigmoid lumen
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4  Therapeutic Approaches
4.1  Surgery
All medical operable patients with endometrial 
cancer should be considered for surgery (Koh 
et al. 2014).
The standard surgical approach of endome-
trial cancer consists of total hysterectomy with 
bilateral salpingo-oophorectomy, assessment of 
the abdominal cavity with biopsies of suspicious 
peritoneal lesions, cytology of peritoneal wash-
ing, and at least excision of enlarged lymph nodes 
(Koh et al. 2014).
Although, systematic pelvic and para-aortic 
lymphadenopathy is considered part of FIGO 
surgico-pathological staging, there is still no 
consensus if it should be performed in cases of 
treatment of stage I endometrial cancer 
(Koh et al. 2014; Colombo et al. 2013; Soliman 
et al. 2010).
A randomized study has shown that in patients 
where systematic lymphadenectomy was per-
formed, a higher rate of postoperative complica-
tions was detected with no improvement of 
disease-free and overall survival rates (Benedetti 
Panici et al. 2008). The ASTEC surgical trial also 
concluded that pelvic lymphadenectomy in 
patients with early disease did not improve over-
all or recurrence-free survival (ASTEC study 
group et al. 2009). These two studies had impor-
tant limitations and caution must be taken to 
avoid overinterpretation.
On the other hand, a large retrospective study, 
the SEPAL study, showed survival benefits in 
patients with intermediate (FIGO IA and IB, 
grade 3 endometrioid carcinoma; FIGO IB, grade 
1 and 2 endometrioid carcinoma with lympho-
vascular space invasion; FIGO IC and II endome-
trioid carcinoma; any type of type 2 endometrial 
cancer) and high risk (FIGO III and IV endome-
trioid carcinoma) endometrial carcinoma when 
a
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Fig. 26 Stage IVA endometrioid carcinoma that invades 
the bladder in a 76-year-old woman. (a) Sagittal 
T2-weighted image; (b) axial T2-weighted image; (c) 
axial oblique 3D fat-suppressed T1-weighted sequence 
after the administration of gadolinium in the equilibrium 
phase (120 s); (d) axial diffusion-weighted image 
(b = 1000 s/mm2); (e) ADC map. T2-weighted images 
show disruption of the hypointense signal of the bladder 
wall and mucosal invasion. There is tumoral enhancement 
within the lumen. The tumor shows also marked restricted 
diffusion, which can also be seen in the bladder lumen
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submitted to combined pelvic and para-aortic 
lymphadenectomy (Todo et al. 2010).
Women with stage II should be considered for 
radical hysterectomy with bilateral salpingo- 
oophorectomy and pelvic and para-aortic lymph-
adenectomy (Colombo et al. 2013).
In patients with a good performance status with 
advanced stage disease (FIGO stage III and IV), 
maximum debulking surgery of resettable tumors 
should be performed. Anterior and posterior pel-
vic exenteration can be considered for stage IVA 
disease as well as palliative surgery in patients 
with metastatic disease (Colombo et al. 2013).
Women with serous, clear-cell carcinomas 
and carcinosarcomas should be submitted to the 
same surgical-pathological staging of ovarian 
cancer (Koh et al. 2014). Serous and clear-cell 
carcinomas can occur in atrophic endometrium 
and may present with distant disease even  without 
myometrial invasion; therefore, omentectomy, 
diaphragmatic cytology or biopsy, and random 
peritoneal biopsies should be performed (Koh 
et al. 2014; Colombo et al. 2013). Pelvic and 
para-aortic lymphadenectomy is mandatory 
(Colombo et al. 2013).
4.2  Adjuvant Treatment
Radiation therapy is usually used in the adjuvant 
setting, in the form of external beam radiation 
therapy (EBRT) and vaginal brachytherapy 
(VBT).
The purpose of adjuvant radiation therapy is to 
eliminate microscopic disease in the lymph nodes 
and in the central pelvic region, including the vagi-
nal cuff; thus reducing the risk of recurrence.
According to the 2014 guidelines of the 
American Society for Radiation Oncology 
(ASTRO), patients with endometrioid  carcinoma 
a b
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Fig. 27 Stage IVB disease (a) axial T2-weighted image 
showing a pulmonary metastasis (arrow); (b) axial 
T2-weighted image showing an umbilical metastasis 
(Sister Mary Joseph node) (dashed arrow); (c) axial 
T2-weighted image showing hepatic metastasis (dotted 
arrows) and a left adrenal metastasis (asterisk)
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that do not require adjuvant radiotherapy (RT) 
are women with no residual disease in the hys-
terectomy specimen and patients with grade 1 or 
2 endometrial cancer with no myometrial inva-
sion or with <50 % of myometrial invasion, 
especially when no high risk features are pres-
ent (Klopp et al. 2014). Patients with grade 3 
endometrioid carcinoma without myometrial 
invasion and patients with grade 1 or 2 cancer 
with <50 % of myometrial invasion and higher 
risk factors, such as being age >60 years and/or 
lymphovascular space invasion, can be ade-
quately treated with or without VBT (Klopp 
et al. 2014).
These guidelines also identify the patients 
with endometrioid cancer for whom vaginal cuff 
brachytherapy is as effective as pelvic radiation 
therapy and consequently should be preferred. 
These patients are women with grade 1 or 2 can-
cers with ≥50 % of myometrial invasion and 
women with grade 3 tumors with <50 % of myo-
metrial invasion (Klopp et al. 2014).
In order to decrease pelvic recurrence, the fol-
lowing women with early phase endometrial can-
cer should receive adjuvant EBRT: patients with 
stage I, grade 3 cancer with ≥50 % of myometrial 
invasion or patients with cervical stromal inva-
sion; patients with stage I, grade 1 or 2 cancer, 
with ≥50 % of myometrial invasion and other 
risk factors such as being of age >60 years and/or 
lymphovascular space invasion (Klopp et al. 
2014).
If there is a negative prognostic factor, pelvic 
RT and/or chemotherapy should be performed for 
stage I and stage II disease (Colombo et al. 2013).
In patients with stage III and IVA disease, 
external EBRT and adjuvant chemotherapy are 
justifiable options. These patients can be con-
sidered for concurrent chemoradiation followed 
by adjuvant chemotherapy (Klopp et al. 2014).
If metastatic disease is present, chemotherapy- 
radiotherapy can be performed for palliative 
treatment (Colombo et al. 2013).
Patients with serous carcinomas, clear-cell 
carcinomas, and carcinosarcomas should be 
considered for platinum-based adjuvant chemo-
therapy with or without radiation therapy (Koh 
et al. 2014).
4.3  Fertility-Sparing Treatment
Fertility-sparing treatment with progestin hor-
monal therapy may be considered for women 
who express the desire to preserve fertility and 
have atypical endometrial hyperplasia or grade 1 
endometrioid carcinoma without myometrial 
involvement in MR (Jafari Shobeiri et al. 2013; 
Kesterson and Fanning 2012; Colombo et al. 
2016). However, this is not the standard of care 
and the decision to proceed with conservative 
management is associated with several hazards. 
Risks include an inadequately staged and treated 
advanced endometrial cancer; the presence of a 
synchronous or meta-synchronous cancer; the 
presence of an inherited genetic predisposition; 
and the absence of standard medical management 
and surveillance (Kesterson and Fanning 2012).
5  Follow-Up and Recurrent 
Endometrial Carcinoma
The majority of recurrences will occur within the 
first 3 years (80 %) (Tirumani et al. 2013). 
However, only 15 % of patients will develop 
recurrent disease (Sala et al. 2013; Magrina et al. 
2011).
The recommended follow-up is a clinical and 
gynecological exam at 3–4 months intervals dur-
ing the first 2 years and then every 6 months until 
5 years (Colombo et al. 2013).
During follow-up, radiological exams should 
only be performed if clinically indicated 
(Colombo et al. 2013).
Most of endometrial cancer recurrences occur 
in the lymph nodes (46 %) and in the vaginal 
vault (42 %) (Sohaib et al. 2007). The perito-
neum and lungs are also reported sites of recur-
rence, although less frequent (Sohaib et al. 2007).
MR imaging is very useful in diagnosing vagi-
nal vault recurrences, which characteristically 
display the same signal characteristics as of those 
of the primary tumor (Tirumani et al. 2013). They 
tend to appear as a mass disrupting the low signal 
intensity of the vaginal vault (Sala et al. 2013). 
MR in these cases plays a role in defining surgi-
cal resectability of pelvic recurrences.
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PET-CT has shown high sensitivity (93 %), 
specificity (93 %), and accuracy (93 %) in detect-
ing recurrent disease (Kitajima et al. 2008). 
However, more prospective larger studies must 
determine its role for routine screening (Salani 
et al. 2011).
5.1  Treatment of Recurrence
Treatment of recurrence varies according to the 
site, to previous treatments, and to the initial 
stage of the disease.
Vaginal recurrence is the most common and 
the standard of treatment is EBRT plus VBP 
(Colombo et al. 2013).
Central pelvic recurrence is usually treated 
with surgery and radiation therapy, whereas 
regional pelvic recurrence is treated with 
 radiation therapy plus chemotherapy if possible 
(Colombo et al. 2013).
Recurrent serous and clear-cell carcinomas 
should be treated with the same chemotherapeu-
tic regimens of ovarian cancer (Colombo et al. 
2013).
6  Prognosis
As stated previously, endometrial carcinoma gen-
erally has a good outcome. Prognostic factors 
include histological subtype; histological grade; 
tumor stage; depth of invasion; and lymphovas-
cular space invasion (Colombo et al. 2013).
Reported 5-year survival rates for stage IA 
and IB are of 88 % and of 75 %, respectively. The 
prognosis of the different types of stage III sub-
stages differs significantly from one another, with 
estimated 5-year survival rates of 58 % for stage 
IIIC1 and of 47 % for stage IIIC2. Stage IV disease 
5-year survival is estimated at 15–17 % 
(American Cancer Society 2016).
The presence of lymph node metastasis, 
namely para-aortic, has shown to have a strong 
effect on prognosis (Todo et al. 2010). Tumor 
grade, lymphovascular space involvement, and 
the depth of myometrial invasion have been 
reported as high risk factors for the tumoral 
involvement of lymph nodes (Patel et al. 2010).
Invasion of the outer half of the myometrium 
is also strongly associated with a diminished 
5-year survival rate (Patel et al. 2010; Amant 
et al. 2005). Furthermore, it was demonstrated 
that patients with lymphovascular space involve-
ment had an overall 5-year survival rate of 64 %, 
and on the other hand women without lympho-
vascular space involvement had an overall 5-year 
survival rate of 88 % (Colombo et al. 2013).
 Conclusion
Magnetic resonance imaging is not considered 
in the International Federation of Gynaecology 
and Obstetrics staging system. However, it 
plays a relevant role in the preoperative staging 
of endometrial carcinomas, helping to define 
the best therapeutic approaches. Moreover, it is 
important in the diagnosis of treatment compli-
cations, in the surveillance of therapy response, 
and in the assessment of recurrent disease.
Functional MR techniques and specific 
MR sequence planes play an important role in 
preventing errors in endometrial cancer 
staging.
To help prevent diagnostic errors and in 
order to guide appropriate therapeutic man-
agement, radiologists should be aware of 
common magnetic resonance imaging endo-
metrial appearances for all stages and the fre-
quent mistakes in the assessment of 
endometrial cancer.
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